Now I have all the information needed. Let me produce the consolidated review.

## Summary
This paper curates open-source PROTAC data (from PROTAC-DB and PROTAC-Pedia) into 16 ML-ready datasets with careful handling of missing activity metrics, no SMILES leakage across splits, and balanced validation sets. It also provides an open-source, configurable PyTorch-based toolkit for predicting PROTAC degradation activity, supporting multiple molecular representations (fingerprints, graphs, SMILES BERT). The best models achieve 71.4–72.6% validation accuracy and 0.73 ROC-AUC — below but in the ballpark of DeepPROTACs (77.95%, 0.847) with simpler representations.

## Strengths
- **Systematic data curation from noisy public sources.** The pipeline extracts cell type via BERT-based NER, retrieves POI sequences from Uniprot via web scraping, handles missing Dmax/DC50 via binning and dose-response curve interpolation, and recalculates PROTAC-Pedia entries to a consistent activity threshold (Section 5.1). This transforms raw, non-ML-ready database entries into structured data — prior work (DeepPROTACs) did not document this level of curation or provide open datasets.
- **16 well-defined datasets with rigorous split design.** All datasets prevent SMILES overlap between train/validation/test, enforce a 50/50 active/inactive ratio in validation sets, and vary split ratios (80/20, 90/10, 95/5, 99/1) as well as augmentation and test-source configurations (Table 2). This systematic variation enables controlled study of how data quantity, augmentation, and distribution shift affect performance.
- **Open-source, modular toolkit enabling reproducibility.** The ProtacDataset class supports multiple molecular representations (Morgan/MACCS fingerprints, PyTorch Geometric graphs, tokenized SMILES for BERT) and non-molecular features (E3 ligase, cell type, POI sequence). Hyperparameter tuning is integrated via Optuna + PyTorch Lightning CLI. The code is provided at an anonymous repository with configuration files — contrast with DeepPROTACs whose code is not open.
- **Honest reporting of negative results and limitations.** The paper documents that data augmentation generally harms performance (Section 7.4), that the dummy (majority-class) model often beats learned models in test accuracy due to class imbalance (Section 7.3), that test F1 scores are low (0.34 average), that OOD generalization drops substantially (mean F1 drop of 0.39), and that proper POI-based or linker-based OOD splits could not be constructed due to data limitations (Section 7.6). This transparency is valuable for future work.

## Weaknesses

### Fatal
None

### Major
- **Overclaimed comparison to state-of-the-art.** The abstract and conclusions state that performance is "comparable to state-of-the-art" and that the models achieve "competitiveness with existing methods." The best reported accuracy (71.4% on the AC dataset; 72.6% on the non-AC 80/20 split) and ROC-AUC (0.73) are materially below DeepPROTACs' 77.95% and 0.847 — a gap of ~6–6.5% in accuracy and ~0.117 in AUC. The claim of "possible outperformance on others" (Section 7.1) is not backed by any specific numbers showing outperformance. The claim that the approach is "less computationally complex" is asserted without any supporting evidence (no runtime, parameter count, FLOPs, or inference time comparison). These claims should be dropped or substantially qualified to match the evidence presented.

- **Accuracy is a misleading primary metric and the headline numbers downplay more informative metrics.** The paper itself shows that the dummy (majority-class) model achieves the highest test accuracy in many configurations (Section 7.3), yet accuracy is used as the headline metric in the abstract (71.4% validation accuracy). The F1 scores on test sets are low (0.36 for XGBoost, 0.34 average across models — Section 7.3). The abstract and conclusion should lead with F1, AUC, or precision-recall to give a realistic picture, or at minimum place accuracy in proper context alongside these metrics.

- **No out-of-distribution generalization is demonstrated.** The paper correctly identifies OOD generalization as critical and notes that it could not construct meaningful OOD splits (e.g., by POI or linker) due to insufficient and imbalanced data (Section 7.6). While this admission is honest, it means the paper provides zero evidence that the models would generalize to new proteins or linkers — which is the primary real-world use case. Without at least one controlled OOD scenario, claims about the model's practical utility remain unsubstantiated. This is a limitation the paper acknowledges but does not adequately caveat in its conclusions.

- **No statistical significance or confidence intervals.** All results appear to come from single runs with no reported variance. Given the small dataset sizes (hundreds to low thousands), performance could vary substantially across random seeds or data splits. Standard deviations, confidence intervals, or at minimum the number of runs averaged should be reported.

### Minor
- **Abstract selects a non-maximal result as "best."** The abstract reports 71.4% validation accuracy as the best result, but the MLP model on the 80/20 (non-augmented) dataset achieves 72.6% (Section 6.2, line 154). The paper's justification (71.4% comes from the configuration with a validation set close in size to DeepPROTACs) is reasonable but not stated in the abstract, creating an appearance of cherry-picking.

- **Several methodological details are underspecified for full reproducibility.** The dose-response curve interpolation method (linear? spline?) is not specified (Section 5.1). The criteria for discarding "too steep curves or hook effect" entries are not quantified. The accuracy of the BERT-based NER for cell type extraction is not reported — if many entries have noisy or missing cell types, the one-hot encoding adds noise. These are addressable but currently hinder precise replication.

- **The "limitations of 2D representations" hypothesis (Section 7.2) is not tested.** The paper attributes the performance ceiling to 2D representations but does not attempt any 3D representation. This reads as speculation rather than a finding. The statement could be framed more clearly as a hypothesis for future work.

- **Random splits may still permit similarity-based leakage.** The paper prevents exact SMILES overlap between splits, which is good practice. However, structurally similar PROTACs (same warhead, same linker) could still appear across splits under random partitioning, potentially inflating in-distribution performance. The paper critiques DeepPROTACs for this but does not assess its own splits for similarity leakage beyond exact match.

### Trivial
- The paper states "the best models achieved a 71.4% validation accuracy" (abstract) but the MLP on the 80/20 split reached 72.6% (line 154) — minor inconsistency.
- The phrase "despite the lack of any benefti" (line 201) contains a typo ("benefti" → "benefit").

## Nice-to-Haves
- A single controlled comparison to DeepPROTACs on an identical test set (if accessible) or under the same evaluation protocol would substantially strengthen the SOTA discussion.
- An ablation showing the contribution of individual fingerprint types (Morgan vs. MACCS vs. combined) would help understand which molecular features drive predictions.
- Quantifying computational complexity (parameter counts, inference time per molecule) in a simple table would support or refute the "less complex" claim without requiring extensive benchmarks.

## Removed Points
*These points were removed from the main review for the reasons stated below. Treat with caution.*

- **"Cherry-picking the best result from a data augmentation scheme that harms performance."** — Partially inaccurate. The paper notes that XGBoost was "robust" to augmentation (Section 7.5: "the XGBoost model was at least robust to it"), so the best result (71.4% from XGBoost on the AC dataset) is not cherry-picked from a universally harmful scheme. However, the abstract's use of 71.4% when 72.6% exists on a non-augmented setting is a genuine inconsistency (retained as Minor above).
- **"The paper does not demonstrate that its own data splitting avoids leakage."** — The paper explicitly states it prevents SMILES overlap between splits (Section 5.2: "We prevented SMILES (PROTAC) overlap between train, validation, and test sets"). The reviewer's concern about molecular *similarity* leakage (beyond exact match) is a different issue and is retained as a Minor weakness above in modified form.
- **Generic framing weaknesses from the harsh critic** (e.g., "evaluation lacks rigor" as a blanket statement) — removed because they lack specific anchors in the paper. All specific, anchored criticisms are retained in appropriate tiers above.
- **"Missing related works"** — removed per policy (cannot be confirmed without external sources).
- **"Missing appendix content"** — removed per policy (parser strips appendix sections; they exist in original submission).
- **"Formatting nitpicks"** — removed per policy.

## Novel Insights
None beyond the paper's own contributions. The main cross-review insight is that the paper's strongest contribution (open data curation + modular toolkit) is somewhat undermined by inflated SOTA competitiveness claims that the evidence does not support. The data augmentation and OOD generalization findings are genuinely useful negative results for the PROTAC ML community, but the paper's own framing prioritizes the less-supported predictive performance angle.

## Suggestions
1. **Recalibrate the central claims.** Replace "comparable to state-of-the-art" and "competitiveness with existing methods" with precise, honest language: "The curated datasets and open-source toolkit provide a reproducible baseline for PROTAC activity prediction. Our best models achieve 71.4–72.6% validation accuracy (vs. DeepPROTACs' reported 77.95%) and 0.73 AUC, using simpler 2D molecular representations." This framing aligns with the evidence.
2. **Lead with AUC, F1, or precision-recall in the abstract and conclusion.** The dummy model's dominance on accuracy makes accuracy a misleading headline. Report the metrics that tell the complete story.
3. **Add at least one controlled OOD split**, even if small. For example, hold out all PROTACs targeting a specific POI (e.g., the most common one, P10275/androgen receptor) and report results. If data is too limited, state this clearly as a finding about dataset constraints — that itself is useful for the community.
4. **Report variance.** Run each configuration at least 3 times with different seeds and report mean ± std for all metrics.
5. **Specify the interpolation method** (linear, spline, etc.) and the quantitative criteria for discarding steep/hook-effect curves in Section 5.1.

## Score and Decision

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>